A wonder drug: Alternative cure for AIDS, dengue, hepatitis, etc

BEHIND The SCENES

Alfred P. Dizon

(Second of three parts)

(This is the continuation of an account of Dr. Ruben G. Fabunan, inventor of a “wonder drug” which he said, is an alternative cure for AIDS, dengue, hepatitis among others. In this second series are case studies of patients being” cured.”)

Depending on a patient's disease type, severity of condition, age, body build and response to treatment, 5 mg to 40 mg of procaine hydrochloride can be mixed with 1 mg to 4 mg of dexamethasone sodium phosphate per intramuscular injection in order to achieve successful treatment.

If the administration of procaine hydrochloride and dexamethasone sodium phosphate in tablet form is contemplated, the dosage amounts for each drug would increase since drug absorption into the circulatory system would occur during drug passage through the gastrointestinal tract whereas drug delivery by intramuscular injection allows for direct drug absorption into the circulatory system.

In tablet form, the amount of procaine hydrochloride can be present in a range of about 350 mg to 600 mg and the amount of dexamethasone sodium phosphate can be present in a range of about 25 mg to 40 mg depending on a patient's disease type, severity of condition, age, body build and response to treatment.

For patient treatment, in general, dosing intervals are as follows:

For AIDS treatment, one 2 ml compilation for adults or one 1 ml compilation for children can be injected intramuscularly two times a day having an interval of two hours or more between injections. After a series of daily injections for nine to twelve consecutive days, then two injections per day can be given once a week.

Subsequent treatment is determined by laboratory tests for the presence of helper T-cell lymphocytes with CD4 receptors that are susceptible to the HIV envelope glycoprotein gp120. A normal CD4 blood concentration is about 700-1000 cells per cubic millimeter of blood.

As the CD4 cell count decreases, the risk of opportunistic viral, bacterial, fungal and parasitic infections increase. Patient dosages can be adjusted depending on the CD4 count and the patient response to treatment.

For Dengue fever, the 2 ml compilation for adults or the 1 ml compilation for children can be injected intramuscularly two times a day having an interval of two hours or more for three to five consecutive days.

For influenza, the 2 ml compilation for adults or the 1 ml compilation for children can be injected intramuscularly two times a day having an interval of two hours or more for one to two days.

All three viral treatments must be accompanied by supplemental oral rehydration fluids. For a severely ill patient, the dosage interval time can be reduced to one and one half hour.

The above average doses and dosing intervals describe a manner and method of making and using the invention and sets forth the best mode contemplated by the inventor for carrying out his invention but is not to be construed as limiting.

For example, commercially available formulations of procaine hydrochloride and dexamethasone sodium phosphate may be used provided the amounts of these formulations generally follow the guidelines as set forth within this patent specification. The specification of U.S. Pat. No. 5,492,901 is hereby incorporated by reference noting the following differences: The present invention compilation ingredients are similar except epinephrine (as the hydrochloride) 1:50,000 is omitted.

Also, in the present invention the compilation is delivered intramuscularly in different dosage amounts and on a different dosage schedule. Further, the present invention compilation has a surprisingly different use. In the present invention, the compilation treats viral diseases whereas in U.S. Pat. No. 5,492,901 the compilation treats venomous toxin diseases.

Below are documented cases of compassionate experimental treatments from the Fabunan Medical Clinic in Burgos, San Marcelino, Zambales C-2207 Philippines. All experimental administration of the present invention compilation resulted in a compassionate and successful treatment and/or cure. All clinical case studies had patient consent forms signed at the time of treatment. Below are documented accounts of the experimental administration and not a commercial offering of the aforementioned treatment.

Case Number 1; Dengue Fever
E. S., a 55 year old female from Nagbunga, San MarcelinoZambales, Philippines, consulted and treated by the Fabunan Medical Clinic on Aug. 15, 1996 as an outpatient. She had the following complaints; fever of three days duration, maculopapular rash on her chest, lack of appetite and frequent bouts of vomiting. A tourniquet test was positive for Dengue fever and laboratory testing showed a decreased platelet count.

She was treated with intramuscular injections containing 30 mg procaine hydrochloride (1.5 ml of a 20 mg per ml solution) combined with 2 mg of dexamethasone sodium phosphate (0.5 ml of a 4 mg per ml solution) (Denguevir-Fabunan Injection, adult dosage) to make a total volume of 2 ml of injectable solution administered twice daily at a two hour interval and coupled with oral rehydration solution.

The above symptoms gradually disappeared during a five day course of treatment and the patient fully recovered and was discharged from the clinic.
Case Number 2; Dengue Fever

K. P., nine months old, a female, infant child, from San Marcelino, Zambales, Philippines was accompanied by her mother for consultation at the Fabunan Medical Clinic on Sep. 22, 1996 due to intermittent fever (T=38° C.), with skin rashes, itchiness, and loss of appetite. Tourniquet test was positive with presence of petechial hemorrhage indicative of dengue fever.

The patient was treated with intramuscular injections containing 15 mg procaine hydrochloride (0.75 ml of a 20 mg per ml solution) combined with 1 mg of dexamethasone sodium phosphate (0.25 ml of a 4 mg per ml solution) (Denguevir-Fabunan Injection, child dosage) to make a total volume of 1 ml of injectable solution administered twice daily at more than a two hour interval for three days and coupled with supplemental oral rehydration solution.

The patient had an improved appetite, all other signs and symptoms gradually disappeared and on the third day as an outpatient, the patient was discharged from the clinic fully recovered.
Case Number 3; Severe Hemorrhagic Dengue Fever

Per a record at Jose B. Lingad Memorial Hospital (JBLMH). G. D. G., a thirteen year old, male, Jehovah's Witness, residing at San Fernando, Pampanga, Philippines, was admitted to JBLMH at Pampanga on Feb. 17, 1999 due to a history of three day high grade fever, anorexia associated with epistaxis (nose bleeding). Prior to hospitalization, medical consultation was done on an outpatient basis where he was sent home with Cephalexin, an oral antibiotic.

Outpatient laboratory platelet count equaled 200 X 109 /L. (Normal platelet count is 140-340 X 109 /L.) Patient had several bouts of vomiting and loose bowel movements (LBM) so he was eventually admitted to the hospital.

On physical examination, he was weak, slightly sunken eyeballs, dry lips and dry skin with vital signs as follows: Blood pressure, 90/60; Temperature, 37.2° C.; Heart rate, 108 beats/min; Weight, 69 lbs. Tourniquet test was negative.

The patient was managed as a case of Dengue Hemorrhagic fever with moderate dehydration. He was placed on nothing per orem (NPO), a nasogastric tube (NGT) was inserted, intravenous (IV) fluids were given along with Paracetamol as well as Ranitidine as medications.

The following are initial laboratory results: Blood Hemoglobin, 134 g/L; hematocrit, 0.44 g/L; clotting time and bleeding time were normal, stool positive for occult blood and Trichuris ova; Urine, 0-2 red blood cells; pus cell, 0-1 hpf. Platelet count on admission was 147 X 109 /L showing a drop from the count taken two days prior to hospitalization.

During the patient's twenty four hour stay in the hospital, coffee ground materials were noted coming out from the NGT. LBM and vomiting slowly calmed down. Vital signs were apparently stable except for fluctuating temperature.

On the second hospital day, he had episodes of epistaxis and gum bleeding. He complained of abdominal pain and there was a gastrointestinal bleeding as seen with a continuous flow of coffee ground materials from the NGT.

A dropping blood pressure, 80/40 was noted. There was a drop of hemoglobin (119 g/L) and his hematocrit was 0.39 g/L. Another IV line was started and Dopamine was hooked to elevate or stabilize his blood pressure. The patient, due to religious belief as a Jehovah's Witness rejected blood transfusions.

On the third hospital day, his blood pressure was 90/60 while his serial platelet count was 100 X 109 /L. The patient's condition was going downhill and the doctors evaluated his status as a poor prognosis.

On Feb. 21, 1999, the patient's parent requested that the hospital discharge the patient against hospital advice and the parent sought assistance from the Fabunan Medical Clinic (FMC) in Zambales, Philippines. The patient was brought to FMC by his parent through a private van. He was non-ambulatory, dehydrated, very weak, apprehensive with two IV lines, one with Dopamine drip and the other NGT.

His vital signs were as follows: Blood pressure, between 100/60 and 90/60; Temperature, 37.2° C.; pulse rate, 64/min; Weight 66 lbs. Petechial hemorrhages were seen all over his body along with skin flashing.

The patient was given two adult doses of Denguevir-Fabunan Injection, 2 cc by intramuscular route at an hour and a half interval. At that time, the patient voided twice. Three hours after the first injection, the patient was seated and was given solid food and sipped some oral fluid solution. NGT was closed. five hours after the initial Denguevir-Fabunan Injection, all IV fluids were terminated/NGT was removed and the patient was advised to take food as tolerated. For the next forty eight hours, he recovered dramatically with better appetite and minimal symptoms.

The parents were very happy after seeing the speedy recovery of their son within three days of Denguevir-Fabunan injection. The patient was discharged from the care of the clinic on Feb. 24, 1999 fully recovered and cured. Ten days after discharge, the patient and his parent came to visit the doctors of FMC just to thank them again for his life.